Advertisement

Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia

      Statin therapy is the gold standard for hypercholesterolemia. However, a significant number of patients cannot achieve their target low-density lipoprotein (LDL) levels despite a maximal dose of statin therapy, and some cannot tolerate statins at all. Approval of proprotein convertase subtilisin/kexin type 9 inhibitors has been revolutionary for those patients. However, the need for frequent injections limits patient compliance with their use. Recently, a twice-yearly injection of inclisiran, a small interfering RNA, has been shown to inhibit hepatic synthesis of proprotein convertase subtilisin/kexin type 9. However, patient randomized clinical trial has been underpowered for clinical end points, necessitating a meta-analysis of those trials. The weighted mean difference was used to describe continuous variables, and pooled risk ratios, calculated using a random effects model, were used to describe discrete variables. Data from 3 randomized clinical trials comprising 3,660 patients showed that inclisiran decreased LDL cholesterol levels by 51% (95% Confidence Interval, 48 to 53%; p < 0.001) compared with placebo. It was associated with a 24% lower major adverse cardiovascular events rate (risk ratios = 0.76; 95% Confidence Interval, 0.61 to 0.92). It also significantly decreased total cholesterol by 37%, apolipoprotein B by 41%, and non high-density lipoprotein (HDL) cholesterol by 45% (all p < 0.001). No differences were found in adverse events, abnormalities in liver function tests, or creatine kinase levels between the treatment strategies. However, a mild injection site reaction occurred more frequently in the inclisiran group. In conclusions, in patients with hypercholesterolemia, inclisiran decreased LDL level by 51% without significant adverse effects. Additionally, it was associated with a lower major adverse cardiovascular event rate.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Baigent C
        • Blackwell L
        • Emberson J
        • Holland LE
        • Reith C
        • Bhala N
        • Peto R
        • Barnes EH
        • Keech A
        • Simes J,
        • Collins R
        Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
        Lancet. 2010; 376: 1670-1681
        • Mach F
        • Baigent C
        • Catapano AL
        • Koskinas KC
        • Casula M
        • Badimon L
        • Chapman MJ
        • De Backer GG
        • Delgado V
        • Ference BA
        • Graham IM
        • Halliday A
        • Landmesser U
        • Mihaylova B
        • Pedersen TR
        • Riccardi G
        • Richter DJ
        • Sabatine MS
        • Taskinen M-R
        • Tokgozoglu L
        • Wiklund O,
        • Group ESD
        2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS).
        Eur Heart J. 2019; 41: 111-188
        • Waters DD
        • Brotons C
        • Chiang CW
        • Ferrières J
        • Foody J
        • Jukema JW
        • Santos RD
        • Verdejo J
        • Messig M
        • McPherson R
        • Seung KB,
        • Tarasenko L
        Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.
        Circulation. 2009; 120: 28-34
        • Gitt AK
        • Lautsch D
        • Ferrieres J
        • Kastelein J
        • Drexel H
        • Horack M
        • Brudi P
        • Vanneste B
        • Bramlage P
        • Chazelle F
        • Sazonov V,
        • Ambegaonkar B
        Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.
        Atherosclerosis. 2016; 255: 200-209
        • Zhang H
        • Plutzky J
        • Skentzos S
        • Morrison F
        • Mar P
        • Shubina M,
        • Turchin A
        Discontinuation of statins in routine care settings: a cohort study.
        Ann Intern Med. 2013; 158: 526-534
        • Schmidt AF
        • Pearce LS
        • Wilkins JT
        • Overington JP
        • Hingorani AD,
        • Casas JP
        PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
        Cochrane Database Syst Rev. 2017; 4Cd011748
        • Du H
        • Li X
        • Su N
        • Li L
        • Hao X
        • Gao H
        • Kwong JS
        • Vandvik PO
        • Yang X
        • Nemeth I
        • Mordi IR
        • Li Q
        • Zhang L
        • Rao L
        • Lang CC
        • Li J
        • Tian H,
        • Li S
        Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis.
        Heart. 2019; 105: 1149-1159
        • Ridker PM
        • Tardif JC
        • Amarenco P
        • Duggan W
        • Glynn RJ
        • Jukema JW
        • Kastelein JJP
        • Kim AM
        • Koenig W
        • Nissen S
        • Revkin J
        • Rose LM
        • Santos RD
        • Schwartz PF
        • Shear CL,
        • Yunis C
        Lipid-reduction variability and antidrug-antibody formation with bococizumab.
        N Engl J Med. 2017; 376: 1517-1526
        • Dyrbuś K
        • Gąsior M
        • Penson P
        • Ray KK,
        • Banach M
        Inclisiran-New hope in the management of lipid disorders?.
        J Clin Lipidol. 2020; 14: 16-27
        • Raal FJ
        • Kallend D
        • Ray KK
        • Turner T
        • Koenig W
        • Wright RS
        • Wijngaard PLJ
        • Curcio D
        • Jaros MJ
        • Leiter LA,
        • Kastelein JJP
        Inclisiran for the treatment of heterozygous familial hypercholesterolemia.
        N Engl J Med. 2020; 382: 1520-1530
        • Ray KK
        • Wright RS
        • Kallend D
        • Koenig W
        • Leiter LA
        • Raal FJ
        • Bisch JA
        • Richardson T
        • Jaros M
        • Wijngaard PLJ,
        • Kastelein JJP
        Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol.
        N Engl J Med. 2020; 382: 1507-1519
        • Moher D
        • Shamseer L
        • Clarke M
        • Ghersi D
        • Liberati A
        • Petticrew M
        • Shekelle P,
        • Stewart LA
        Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
        Syst Rev. 2015; 4: 1
        • Higgins JP
        • Altman DG
        • Gotzsche PC
        • Juni P
        • Moher D
        • Oxman AD
        • Savovic J
        • Schulz KF
        • Weeks L,
        • Sterne JA
        The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
        BMJ. 2011; 343: d5928
        • Sterne JA
        • Sutton AJ
        • Ioannidis JP
        • Terrin N
        • Jones DR
        • Lau J
        • Carpenter J
        • Rucker G
        • Harbord RM
        • Schmid CH
        • Tetzlaff J
        • Deeks JJ
        • Peters J
        • Macaskill P
        • Schwarzer G
        • Duval S
        • Altman DG
        • Moher D,
        • Higgins JP
        Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.
        BMJ. 2011; 343: d4002
        • Schwartz GG
        • Steg PG
        • Szarek M
        • Bhatt DL
        • Bittner VA
        • Diaz R
        • Edelberg JM
        • Goodman SG
        • Hanotin C
        • Harrington RA
        • Jukema JW
        • Lecorps G
        • Mahaffey KW
        • Moryusef A
        • Pordy R
        • Quintero K
        • Roe MT
        • Sasiela WJ
        • Tamby JF
        • Tricoci P
        • White HD,
        • Zeiher AM
        Alirocumab and cardiovascular outcomes after acute coronary syndrome.
        N Engl J Med. 2018; 379: 2097-2107
        • Sabatine MS
        • Giugliano RP
        • Keech AC
        • Honarpour N
        • Wiviott SD
        • Murphy SA
        • Kuder JF
        • Wang H
        • Liu T
        • Wasserman SM
        • Sever PS,
        • Pedersen TR
        Evolocumab and clinical outcomes in patients with cardiovascular disease.
        N Engl J Med. 2017; 376: 1713-1722
        • Fitzgerald K
        • White S
        • Borodovsky A
        • Bettencourt BR
        • Strahs A
        • Clausen V
        • Wijngaard P
        • Horton JD
        • Taubel J
        • Brooks A
        • Fernando C
        • Kauffman RS
        • Kallend D
        • Vaishnaw A,
        • Simon A
        A highly durable RNAi therapeutic inhibitor of PCSK9.
        N Engl J Med. 2017; 376: 41-51
        • Ray KK
        • Landmesser U
        • Leiter LA
        • Kallend D
        • Dufour R
        • Karakas M
        • Hall T
        • Troquay RP
        • Turner T
        • Visseren FL
        • Wijngaard P
        • Wright RS,
        • Kastelein JJ
        Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol.
        N Engl J Med. 2017; 376: 1430-1440
        • Fitzgerald K
        • Frank-Kamenetsky M
        • Shulga-Morskaya S
        • Liebow A
        • Bettencourt BR
        • Sutherland JE
        • Hutabarat RM
        • Clausen VA
        • Karsten V
        • Cehelsky J
        • Nochur SV
        • Kotelianski V
        • Horton J
        • Mant T
        • Chiesa J
        • Ritter J
        • Munisamy M
        • Vaishnaw AK
        • Gollob JA,
        • Simon A
        Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.
        Lancet. 2014; 383: 60-68
        • Ray KK
        • Stoekenbroek RM
        • Kallend D
        • Nishikido T
        • Leiter LA
        • Landmesser U
        • Wright RS
        • Wijngaard PLJ,
        • Kastelein JJP
        Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial.
        JAMA Cardiol. 2019; 4: 1067-1075